Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDV-60mer
- Development stage
- Unknown
- Lead developer
- Engeneic
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
EDV-60mer is an investigational, non-targeted EnGeneIC Dream Vector (EDV™) nanocell developed by EnGeneIC Pty Limited. It consists of a bacterially-derived, ~400 nm nanoparticle delivery system loaded with an immunomodulatory 60mer oligonucleotide adjuvant. Unlike targeted EDVs, EDV-60mer lacks a bispecific antibody for tumor-specific targeting; its primary function is to act as an immune stimulant to overcome tumor-induced immunosuppression and enhance anti-tumor immune responses. In clinical settings, it is being evaluated in Phase 1 trials as a combination partner with EGFR-targeted EDVs carrying the super-cytotoxic payload PNU-159682 (EGFR(V)-EDV-PNU) for the treatment of advanced solid tumors lacking curative options.
- Other names
- non-targeted EnGeneIC Dream Vector loaded with 60mer oligonucleotide adjuvant
Beyond the preview
Go deeper on EDV-60mer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDV-60mer.